ABSTRACT
Objective To study and analyze the clinical effects of rhG-CSF combined with chemotherapy in the treatment of acute leukemia. Methods 60 patients with acute leukemia were selected as the study subjects (from February 2015 to April 2017). The control group was given routine chemotherapy, the experimental group was given rhG-CSF on the basis treatment of the control group. Clinical indicators of two groups of patients were compared and analyzed. Results After the corresponding treatment, the effective rate was 63.3% in the experimental group and 43.3% in the control group, and the difference was statistically significant (P<0.05). After treatment, the quality of life score of the control group (62.30±9.20) was significantly lower than the experimental group (76.88±10.90) with statistical difference (P<0.05). The number of neutrophils reduced from 0.1×109/L to 1.5×109/L in the experimental group took (11.23±1.65), and the time for the control group was (18.90±2.78), and the difference between the two groups was statistically significant (P<0.05). There were no serious adverse reactions in the two groups, and the incidence was 10% and 13.3%, which was not statistically significant. Conclusion rhG-CSF combined with chemotherapy in the treatment of acute leukemia has good clinical effect.
ABSTRACT
Objective To study and analyze the clinical effects of rhG-CSF combined with chemotherapy in the treatment of acute leukemia. Methods 60 patients with acute leukemia were selected as the study subjects (from February 2015 to April 2017). The control group was given routine chemotherapy, the experimental group was given rhG-CSF on the basis treatment of the control group. Clinical indicators of two groups of patients were compared and analyzed. Results After the corresponding treatment, the effective rate was 63.3% in the experimental group and 43.3% in the control group, and the difference was statistically significant (P<0.05). After treatment, the quality of life score of the control group (62.30±9.20) was significantly lower than the experimental group (76.88±10.90) with statistical difference (P<0.05). The number of neutrophils reduced from 0.1×109/L to 1.5×109/L in the experimental group took (11.23±1.65), and the time for the control group was (18.90±2.78), and the difference between the two groups was statistically significant (P<0.05). There were no serious adverse reactions in the two groups, and the incidence was 10% and 13.3%, which was not statistically significant. Conclusion rhG-CSF combined with chemotherapy in the treatment of acute leukemia has good clinical effect.